<DOC>
	<DOCNO>NCT00054002</DOCNO>
	<brief_summary>RATIONALE : Photodynamic therapy use light drug make cancer cell sensitive light kill cancer cell . Combining photodynamic therapy surgery may effective treatment malignant mesothelioma . PURPOSE : Phase II trial study effectiveness combine photodynamic therapy surgery treat patient malignant mesothelioma .</brief_summary>
	<brief_title>Surgery Photodynamic Therapy Treating Patients With Malignant Mesothelioma</brief_title>
	<detailed_description>OBJECTIVES : - Determine feasibility adjuvant photodynamic therapy large diffuser fiber patient malignant mesothelioma undergo surgery . - Compare result regimen patient historical control . - Determine toxic effect regimen patient . OUTLINE : This pilot study . Patients receive porfimer sodium IV 5-10 minute day 1 . Patients undergo pleurectomy pleuropneumonectomy follow intracavitary photodynamic therapy day 3 . Patients follow 1 month , every 4 month 2 year , every 6 month 3 year . PROJECTED ACCRUAL : A total 20 patient accrue study within 3 year .</detailed_description>
	<mesh_term>Mesothelioma</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Dihematoporphyrin Ether</mesh_term>
	<mesh_term>Trioxsalen</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm malignant mesothelioma , include follow cell type : Mixed mesothelial Sarcomatous Stage I II disease use Butchart system determine CT scan MRI Disease confine 1 hemithorax No tumor involvement esophagus heart evidence CT scan Pericardial diaphragmatic involvement allow disease limited ipsilateral chest N2 disease allow contralateral pleural involvement No adenocarcinoma nonmesothelioma sarcoma chest wall PATIENT CHARACTERISTICS : Age 18 Performance status ECOG 02 Life expectancy Not specify Hematopoietic WBC great 4,000/mm^3 Platelet count great 100,000/mm^3 Hemoglobin great 8.5 g/dL ( transfusion allow ) Hepatic Bilirubin le 3.0 mg/dL Alkaline phosphatase less 2 time upper limit normal ( ULN ) SGOT le 2 time ULN Renal Creatinine le 3.0 mg/dL Cardiovascular No myocardial infarction within past 6 month Pulmonary Arterial partial pressure carbon dioxide ( pCO_2 ) less 50 torr rest Predicted postoperative FEV_1 least 800 mL maximum oxygen consumption/kg least 15 mL/min Predicted postoperative total lung capacity least 40 % hemoglobin alveolar ventilation Other Not pregnant No concurrent malignancy except nonmelanoma skin cancer No contraindication general anesthetic No history porphyria No indicated sensitivity porfimer sodium PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy More 30 day since prior chemotherapy Endocrine therapy Not specify Radiotherapy No prior radiotherapy chest No prior radiotherapy mesothelioma Surgery Not specify</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2011</verification_date>
	<keyword>localize malignant mesothelioma</keyword>
	<keyword>recurrent malignant mesothelioma</keyword>
	<keyword>epithelial mesothelioma</keyword>
	<keyword>sarcomatous mesothelioma</keyword>
</DOC>